Thursday November 26 2009 | Biotechnology feed | All feeds

BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease

Lamivudine

Lamivudine is a potent nucleoside analog reverse transcriptase inhibitor .It is marketed by GlaxoSmithKline with the brand names Zeffix, Epivir, and Epivir-HBV.Lamivudine has been used for treatment of chronic hepatitis B at a lower dose than for treatment of HIV. It improves the seroconversion of e-antigen positive hepatitis B and also improves histology staging of the liver. Long term use of lamivudine unfortunately leads to emergence of a resistant hepatitis B virus mutant. Despite this, lamivudine is still used widely as it is well tolerated. (From the Wikpedia article Lamivudine.)

Download PDF containing detailed information.PDF Version

Image Results

Loading...

Recent Publications on Lamivudine:

Pubmed Logo
Mortality and drug exposure in a 5-year cohort of patients with chronic liver disease.
BACKGROUND: Chronic liver diseases are common in the general population....
20th November, 2009
Division of General Internal Medicine, Brigham and Women's Hospital, Swiss Med Wkly. 2009 Nov 19.
DOI Direct Link
Treatment of HIV infection: Swedish recommendations 2009.
On 4 previous occasions, in 2002, 2003, 2005 and 2007, the Swedish Medical...
20th November, 2009
From the Department of Clinical Pharmacology, Karolinska University Scand J Infect Dis. 2009;41(11-12):788-807.
Progress in basic and clinical research on HIV resistance: report on the XVIII International HIV Drug Resistance Workshop.
Over nearly two decades, the International HIV Drug Resistance Workshop...
18th November, 2009
Allentown, PA, USA. Antivir Ther. 2009;14(7):1015-37.
DOI Direct Link
Evolution of hepatitis B virus mutation during entecavir rescue therapy in patients with antiviral resistance to lamivudine and adefovir.
BACKGROUND: The efficacy of entecavir (ETV) monotherapy in...
18th November, 2009
Department of Internal Medicine, Konkuk University School of Medicine, Antivir Ther. 2009;14(7):985-93.
DOI Direct Link
Postpartum antiretroviral drug resistance in HIV-1-infected women receiving pregnancy-limited antiretroviral therapy.
BACKGROUND:: Pregnancy-limited antiretroviral therapy (PLAT) drastically...
17th November, 2009
aBrigham and Women's Hospital, Harvard Medical School, Boston, AIDS. 2009 Nov 12.
DOI Direct Link

View more research publications.

Press Releases About Lamivudine:

BioPortfolio Logo
Bristol-Myers Squibb Welcomes NICE Guidance Recommending Baraclude(R) (entecavir) as a Treatment Option for Chronic Hepatitis B 29th August, 2008
UXBRIDGE, England, August 29 /PRNewswire/ -- NICE (National Institute for Health and Clinical Excellence) has published guidance that recommends Baraclude(R) (entecavir) as an option for treatment of
Chronic viral hepatitis: B is for billions 1st March, 2005 Datamonitor
Chronic viral hepatitis: B is for billions Despite recent advances in the treatment and management of hepatitis B, the market is still relatively immature, with several key unmet needs.

BioNews Results for Lamivudine:

RSS Logo
BioPortfolio Logo
Review Finds Pegylated Interferon Is More Effective than Lamivudine for Chronic Hepatitis B, but Study Shows L
HIV and Hepatitis.com:  Nov 18 2009 4:42AM Matching: lamivudine
Trends in Waiting List Registration for Liver Transplantation for Viral Hepatitis in the United States
National AIDS Treatment Advocacy Project:  Nov 7 2009 3:04AM Matching: lamivudine
HIV/AIDS Update - Tentative Approval of Lamivudine and Tenofovir DF Fixed Dose Combination Tablets, 300mg/300m
Pharma Live:  Nov 7 2009 2:57AM Matching: lamivudine
Adefovir Plus Lamivudine Is Effective in Patients With Lamivudine-Resistance Chronic Hepatitis B: Presented at
Doctors Guide:  Nov 2 2009 11:18PM Matching: lamivudine
Lamivudine, Entecavir Both Improved Prognosis in Hepatitis B-Related Acute-on-Chronic Liver Failure: Presented
Doctors Guide:  Nov 2 2009 11:18PM Matching: lamivudine
Promote your company here: BioNewsCast - Press Release Distribution

View more news.

Lamivudine Patents:

USPTO Logo
US Patent No.Title
7589204 Indane compounds as CCR5 antagonists
7598029 Method for identifying HIV-1 protease inhibitors with reduced metabolic affects
7598235 Bile-acid conjugates for providing sustained systemic concentrations of drugs
7598248 Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols, compositions thereof, and methods for their use
7598264 HIV integrase inhibitors

View more patents.

Companies working in the area of Lamivudine from Bioportfolio's Biocorporate database :

BioPortfolio Logo
Company Name

Jinan Lekangxin Pharmacy Co.,Ltd

We are pleased to introduce our company, Jinan Lekangxin Pharmacy Co., Ltd as one of the leading producer and exporters of APIs(active pharmaceutical ingredients) and intermediates in China.Presently...
www.jnjz.com        View full profile
Thumbshot

Flavoxate, Raltitrrexed sale

We are pleased to introduce our company, Jinan Lekangxin Pharmacy Co., Ltd as one of the leading producer and exporters of APIs(active pharmaceutical ingredients) and intermediates in China.Presently...
        View full profile

BioPortfolio Ltd. offers e-mail and postal lists for Lamivudine scientists - we have details of around 501 individuals working on Lamivudine .


This page has been viewed 391 times
Recent Search Terms used to find this page: Lamivudine Market | Add-on combination therapy with adefovir dipivoxil induced renal impairment in patients with lamivudine-refractory hepatitis B virus. | lamivudine market | LAMIVUDINE INTERMEDIATES FROM CHINA | efficiency of baraclude for hepatitis-b | lamivudine market | hepatitis B market lamivudine 2009 | lamivudine and adefovir combo patent | lamivudine costs 2009 | .
Browse BioPortfolio's InDepth service - alphabetically: A B C D E F G H I J K L M N O P Q R S T U V W X Y Z or by Most Publications, recently searched for, or most viewed.

Search for Lamivudine across BioPortfolio, or for Lamivudine Research Reports
Wikipedia excerpt, where present, licenced under the GNU Free Documentation License. Resources from the NCBI applied. Selected MeSH subject headings created and maintained by the US NLM are used in conjunction with additional keywords. 2006-2008 MeSH. Thumbshots from Thumbshots.org

 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.

All rights reserved. All other trademarks recognized.
Copyright 1997-2009 - BioPortfolio Limited.